Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot study of the safety and efficacy of quadrivalent human papillomavirus vaccine (Gardasil) in female subjects with juvenile idiopathic arthritis (JIA)/ seronegative arthritis.

Trial Profile

Pilot study of the safety and efficacy of quadrivalent human papillomavirus vaccine (Gardasil) in female subjects with juvenile idiopathic arthritis (JIA)/ seronegative arthritis.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Jun 2018

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Pharmacodynamics
  • Acronyms CHASE
  • Most Recent Events

    • 04 Mar 2018 Planned End Date changed from 1 Nov 2014 to 30 Sep 2018.
    • 04 Mar 2018 Planned primary completion date changed from 1 Nov 2014 to 30 Jun 2018.
    • 04 Mar 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top